Table 3.

Tazemetostat treatment.

patient	No 1	No 2	No 3	No 4	No 5	No 6
Introduction of tazemetostat	1,5 months after last cht	1,5 months after last cht	3 months after last cht	3 months after last cht	2 months after RT	3 months after RT
State of disease at the introduction of tazemetostat	CR	PR	CR	PR	PR	CR
Initial dose	2 × 1200 mg/m2	2 × 1200 mg/m2	2 × 1200 mg/m2	2 × 1200 mg/m2	2 × 600 mg/m2	2 × 520 mg/m2
Dose modification	No	2 × 950 mg/m2 for bromide toxicity	2 × 600 mg/m2 for hematotoxicity	2 × 520 mg/m2 for hematotoxicity	2 × 1200 mg/m2 At progression	No
Dose 2nd year	2 × 520 mg/m2	Not applicable	2 × 520 mg/m2	2 × 520 mg/m2	Not applicable	2 × 520 mg/m2
State of disease at last FU	Continued CR	Died of tumor progression	Continued CR	Continued PR	Died of tumor progression	Continued CR
Overal survival (months)	32	20	34	30	37	44